Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140855 · ClinicalTrials.gov registry record · Phase 2
A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
A Phase 2 study, sponsored by Ludwig Institute for Cancer Research.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00140855 is a Phase 2 study that was terminated before completion, run by Ludwig Institute for Cancer Research. The registered enrollment target is 6 participants.
The verdict
NCT00140855, a Phase 2 study, was terminated before completion, sponsored by Ludwig Institute for Cancer Research.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether immune therapy with anti-CTLA-4 antibody is effective in people with advanced synovial sarcoma.
Interventions
- BIOLOGICAL ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2005-06-08 |
| Est. Completion | 2007-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00140855
The ClinicalTrials.gov registry entry for NCT00140855 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ludwig Institute for Cancer Research, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ipilimumab is the first listed.
NCT00140855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00140855 about?
NCT00140855 is a clinical study titled "A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma". The purpose of this study is to determine whether immune therapy with anti-CTLA-4 antibody is effective in people with advanced synovial sarcoma.
What is the current status of trial NCT00140855?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2005-06-08. Estimated completion is 2007-07-01.
What interventions are being tested in trial NCT00140855?
The interventions under investigation include: ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00140855?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.